The U.S. FDA this week issued new guidelines for labeling of Non-Steroidal Anti-Inflammatory Drugs (NSAID) and Acetaminophen (Paracetemol) used for pain relief and fever reduction due to concerns about overdosing and co-administration with Alcohol. TDS wo More
APR has successfully designed and completed the development of Veloderm, an innovative Biotechnology device for wound healing and licensed to Medestea the exclusive worldwide marketing rights More
Sinclair Pharma plc, the specialty pharmaceutical ompany, announces that it has licensed the exclusive US rights of one of its key products, Decapinol® Rinse, to OraPharma, Inc., a subsidiary of Johnson & Johnson More
Invented at The University of Western Ontario, a novel therapy system for treating dysphagia has been licensed to Trudell Medical International (TMI) for development and world-wide distribution. Therapy system is currently undergoing clinical testing More
Sinclair Pharma plc announces today that Decapinol®, its oral rinse for the treatment of gingivitis (gum inflammation), has received registration approval from the FDA as a prescription medical device. More
UCL Professor Alex Seifalian's breakthrough work in bypass grafts for cardiovascular treatment has been recognized by the highly prestigious Medical Futures Innovation Awards panel as 'Winner of The Overall Cardiovascular Innovation Award'. More
Zambon will license Vectura's PowderHale(tm) pulmonary formulation technology for the development and commercialisation of a new dry powder inhaler product. More
Frost & Sullivan the international management consultancy, has awarded its prestigious 2006 Oral and Dental Care Product of the Year Award to Sinclair Pharma plc for Decapinol® More
Displaying 1..10 of 37 -
per page
Next page
Order by
All rights reserved. Terms and Conditions | Contact us
